Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.

Falkner, E. and Wild, C. (2007): Cell salvage for minimising perioperative allogeneic blood transfers]. HTA-Newsletter 59: 3.

Geiger-Gritsch, S. (2010): Bendamustine (Ribomustin®/Treanda®/ Levact®) for indolent non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and multiple myeloma. DSD: Horizon Scanning in Oncology 10.

Hintringer, K. (2010): Plerixafor (Mozobil ®) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma. DSD: Horizon Scanning in Oncology 08.

Langer, T. (2006): [Stem cell transplantation for acute leukemia]. HTA-Newsletter 52: 2-3.

Nachtnebel, A. (2009): Azacitidine (Vidaza®) for the treatment of myelodysplastic syndromes. DSD: Horizon Scanning in Oncology 01.

Nachtnebel, A. (2009): Ibritumomab tiuxetan (Zevalin®) as consolidation therapy after first remission in patients with follicular lymphoma. DSD: Horizon Scanning in Oncology 05.

Warmuth, M. (2009): Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 04.

Warmuth, M. and Mad, P. and Wild, C. (2009): Haemocomplettan® P alone or in combination with Fibrogammin® P in acquired hypofibrinogenemia. HTA-Projektbericht 039.

Wild, C. (2007): [FDA: Safety warning on erythropoietin]. ÖKZ: Österreichische Krankenhauszeitung 48 (07).

Wild, C. (2007): [FDA: Safety warning on erythropoietin]. HTA-Newsletter 58: 4.

Wild, C. (2005): [Immunoglobulin in neonates and preterm infants]. HTA-Newsletter 41: 2-3.

Wild, C. (2005): . HTA-Newsletter 40: 4.

Wild, C. (2005): [Autologous blood donation]. HTA-Newsletter 38: 2.

Wild, C. (2004): [Rituximab (MabThera®) as treatment for non-Hodgkin's lymphoma]. HTA-Newsletter 32: 3.

Wild, C. (2004): [Sentinel node biopsy (SNB) in breast cancer]. HTA-Newsletter 24: 2-3.

Wild, C. (2003): [Tumour vaccination]. HTA-Newsletter 19: 4.

Wild, C. (2003): [Erythropoietin: The impact of HTA]. ÖKZ: Österreichische Krankenhauszeitung 44 (12): 9-10.

Wild, C. (2003): [Erythropoietin: The impact of HTA] . Mitteilungen der Sanitätsverwaltung 104 (9): 23.

Wild, C. (2002): Erythropoietin in tumor anemia - for whom is effective?. International Journal of Cancer 13 (Supplement): 70.

Wild, C. (2001): [Stem cell research, quo vadis? Editorial]. HTA-Newsletter 03: 1-2.

Wild, C. (2001): [Stem cell research, quo vadis?]. ORF ON Science.

Wild, C. (2001): [Erythropoietin for anaemic tumour patients]. HTA-Newsletter 01: 2.

Wild, C. (2001): [Stem cells: Quo vadis?]. ITA-Newsletter September 2001: 8-9.

Wild, C. (2001): [Assessing medical interventions: Erythropoietin in tumour anaemia]. TA-Datenbank-Nachrichten (01, Sonderheft): 51-55.

Wild, C. (2000): [EPO for cancer related anaemia]. ITA-Newsletter April 2000: 5.

Wild, C. (2000): [Erythropoietin in patients with fatigue syndrome]. forum dr. Med. (13): 4-5.

Wild, C. and Jonas, S. (2001): [Health policy decisions between rationing and rationalisation as demonstrated by the example of erythropoietin in tumour anaemia]. Das Gesundheitswesen 63 (2): 221-225.

Wild, C. and Jonas, S. (2000): [EPO in cancer anaemia]. ITA-Newsletter September 2000: 2-3.

Wild, C. and Jonas, S. (2000): [Erythropoietin in tumour anaemia. An assessment]. ITA-Projektbericht 15.

Wild, C. and Jonas, S. (2000): [Erythropoietin (EPO) in tumour anaemia]. Newsletter der Österreichischen Gesellschaft für Public Health (4): 1-2.

Wild, C. and Mathis, S. and Guba, B. and Gartlehner, G. (2008): [Rheopheresis in patients with age-related macular degeneration, sudden hearing loss or tinnitus, diabetes. Systematic review]. Decision Support Document 12.

Zechmeister, I. and Mathis, S. and Guba, B. and Gartlehner, G. (2008): [LDL apheresis. Systematic review]. Decision Support Document 07.